On November 20, the question of which country will host the European Medicines Agency post- Brexit will finally be settled, at the European Council’s General Affairs (Art. 50) meeting.
Voting from each member state will end months of speculation, and the hopes of 18 candidatures. One lucky winner will take home the honor of hosting one of the world’s preeminent medicines regulators, and everything that goes with it.
As the bidding process draws to its conclusion, The Pharma Letter has attempted to read the political tea leaves, speaking to representatives from the bidding nations and compiling the available evidence to assess the most likely outcome.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze